Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ACP3 | P15309 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5940495 | 0.90 | CYP2D6 (0.48) | CYP1A2CYP2D6CYP2C19SRCALDH1A1 | |
| SCHEMBL8496310 | 0.90 | CYP2D6 (0.48) | CYP1A2CYP2D6CYP2C19SRCALDH1A1 | |
| Hydrochloric Acid SCHEMBL1311457 | 0.88 | CYP2D6 (0.47) | CYP1A2CYP2D6CYP2C19SRCALDH1A1 | |
| SCHEMBL1814697 | 0.88 | CYP1A2 (0.39) | CYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL1810690 | 0.82 | ALDH1A1 (0.44) | ALDH1A1NPC1KDM4E | |
| SCHEMBL1809439 | 0.80 | ALDH1A1 (0.39) | CYP2C19SRCALDH1A1ACP3ANPEP | |
| SCHEMBL1810262 | 0.78 | ACP3 (0.45) | ACP3ANPEP | |
| SCHEMBL29943118 | 0.78 | CYP2D6 (0.43) | CYP1A2CYP2D6CYP2C19SRCALDH1A1 | |
| SCHEMBL22074727 | 0.76 | BLM (0.47) | CYP1A2CYP2D6CYP2C19SRCALDH1A1 | |
| SCHEMBL22074723 | 0.76 | BLM (0.47) | CYP1A2CYP2D6CYP2C19SRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3040340-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-11-14 | — | — | EP | disclosed |
| EP-2955190-B1 | Chemical compounds | NuCana plc (GB) | 2018-03-28 | — | — | EP | disclosed |
| EP-1646639-B1 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | NUCANA BIOMED LTD (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3040340-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-07-06 | — | — | EP | disclosed |
| EP-2955190-A2 | Chemical compounds | NuCana BioMed Limited (GB) | 2015-12-16 | — | — | EP | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| CN-1328565-A | Antiviral purine derivatives | UNIV CARDIFF (GB) | 2001-12-26 | — | — | CN | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | CYP1A2 3861/4885CYP2D6 2620/4885CYP2C19 2835/4885 |
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | CYP1A2 3072/4885CYP2D6 1659/4885CYP2C19 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.